ERBB2 and breast neoplasm: For HER2 (−) breast tumor cells MDA-MB-231, the tumor-specific targeting rate was also increased from 5.4% of NBs-Affibody to 99.3% of IR783-NBs-Affibody (Figure 5(c)).